NCT01160445 2015-10-28Phase II Study of Aldesleukin (IL-2) Following the Administration of Zanolimumab (Anti-CD4mAb) in Metastatic Melanoma and Metastatic Renal CancerNational Institutes of Health Clinical Center (CC)Phase 2 Terminated9 enrolled 9 charts